Science & Enterprise subscription

Follow us on Twitter

  • A company developing cancer therapies with stem cells from human placentas says FDA cleared its request to start a… https://t.co/FLZsulrKXd
    about 11 hours ago
  • New post on Science and Enterprise: FDA Clears Placenta Cell Brain Cancer Trial https://t.co/aqKU4Eo3Fw #Science #Business
    about 11 hours ago
  • A medical engineering team developed personalized organoid lab models with cancer cells that predict patient respon… https://t.co/PVhclsAMf1
    about 15 hours ago
  • New post on Science and Enterprise: Organoids Developed for Precision Cancer Treatments https://t.co/SS8nlwYSxq #Science #Business
    about 15 hours ago
  • Thank you @CodeIsGo_com https://t.co/MXkfhmjIxD
    about 1 day ago

Please share Science & Enterprise

Pharma Gains Fibrosis Technology in $1B+ Deal

Stuart Cook

Drug maker Boehringer Ingelheim is acquiring an antibody technology that blocks actions of a signaling protein associated with a range of fibrosis diseases. . . . → Read More: Pharma Gains Fibrosis Technology in $1B+ Deal

Vaccine Developer Gains $11M in Early Funds

Baby with microcephaly

A company designing vaccines delivered with a microneedle patch to prevent infectious diseases is raising $11 million in its first venture funding round. . . . → Read More: Vaccine Developer Gains $11M in Early Funds

Trial Underway Testing Crispr-Based Antibiotic

E. coli

A clinical trial is recruiting participants to test an antibiotic made with engineered viruses, in people threatened with urinary tract infections from E. coli bacteria. . . . → Read More: Trial Underway Testing Crispr-Based Antibiotic

A.I. Discovery Companies to Find Rare Disease Drugs

Synthetic biology

A joint venture of two drug discovery and design companies aims to create new biotechnology businesses to find drugs for treating rare diseases. . . . → Read More: A.I. Discovery Companies to Find Rare Disease Drugs

Biotech Options Enzyme Inhibitors for Lung Cancer

Human lungs illustration

A biotechnology company developing inhaled drugs for respiratory diseases agreed to provide Johnson & Johnson with access to its technology for treating lung cancer. . . . → Read More: Biotech Options Enzyme Inhibitors for Lung Cancer

Science & Enterprise Year in Review

Crispr explainer

Our most-viewed new story is from an academic/industry research team in Australia that tells how a synthetic cannabidiol, or CBD, compound is as effective as current antibiotics against a class of microbes. . . . → Read More: Science & Enterprise Year in Review

Infographic – Biotech Index Zooms to New High

NBI chart

Since October, the Nasdaq Biotechnology Index rose steadily to a new high for the year, as shown in this weekend’s infographic. . . . → Read More: Infographic – Biotech Index Zooms to New High

Synthetic Bio Cancer Immunotherapy Company Acquired

Natural killer cell

A biotechnology company creating synthetic proteins that invoke the immune system to fight cancer is being acquired by drug maker Astellas Pharma. . . . → Read More: Synthetic Bio Cancer Immunotherapy Company Acquired

Commentary – New Models Needed for Antibiotic Resistance

MRSA bacteria

Many parts of a new model for fighting antibiotic resistance are in development, and the pieces still need to be assembled, but the outline of a precision-medicine rather than mass-produced drug model is beginning to emerge. . . . → Read More: Commentary – New Models Needed for Antibiotic Resistance

Tomato Genetics Altered for Urban Farms

Gene-altered tomatoes

Plant scientists used a genome-editing technique to produce varieties of tomatoes better suited for growing on urban farms and other small plots. . . . → Read More: Tomato Genetics Altered for Urban Farms